Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial.

Saved in:
Bibliographic Details
Title: Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial.
Authors: Aggarwal R; Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, USA., Bhatt DL; Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: dlbhattmd@post.harvard.edu., Szarek M; Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA; CPC Clinical Research and University of Colorado Anschutz Medical Campus, Aurora, CO, USA; State University of New York Downstate School of Public Health, Brooklyn, NY, USA., Cannon CP; Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, USA., Leiter LA; Li Ka Shing Knowledge Institute, St Michael's Hospital, University of Toronto, Toronto, ON, Canada., Inzucchi SE; Yale School of Medicine, New Haven, CT, USA., Lopes RD; Duke University School of Medicine, Durham, NC, USA., McGuire DK; University of Texas Southwestern Medical Center and Parkland Health, Dallas, Texas, USA., Lewis JB; Vanderbilt University Medical Center, Nashville, Tennessee, USA., Riddle MC; Oregon Health and Science University, Portland, OR, USA., Davies MJ; Lexicon Pharmaceuticals, The Woodlands, TX, USA., Banks P; Lexicon Pharmaceuticals, The Woodlands, TX, USA., Carroll AK; Lexicon Pharmaceuticals, The Woodlands, TX, USA., Scirica BM; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Ray KK; Department of Primary Care and Public Health, Imperial College London, London, UK., Kosiborod MN; Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, MO, USA., Cherney DZI; University Health Network, Toronto General Hospital Research Institute, University of Toronto, Toronto, ON, Canada., Udell JA; Women's College Hospital and Peter Munk Cardiac Centre, Toronto General Hospital, University of Toronto, ON, Canada., Verma S; Li Ka Shing Knowledge Institute, St Michael's Hospital, University of Toronto, Toronto, ON, Canada., Mason RP; Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, USA; Elucida Research, Beverly, MA, USA., Pitt B; University of Michigan, Ann Arbor, MI, USA., Steg PG; Université Paris-Cité, INSERM U1148 and AP-HP Hôpital Bichat, Paris, France; French Alliance for Cardiovascular Trials, Paris, France.
Source: The lancet. Diabetes & endocrinology [Lancet Diabetes Endocrinol] 2025 Apr; Vol. 13 (4), pp. 321-332. Date of Electronic Publication: 2025 Feb 14.
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: The Lancet, Diabetes & Endocrinology Country of Publication: England NLM ID: 101618821 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-8595 (Electronic) Linking ISSN: 22138587 NLM ISO Abbreviation: Lancet Diabetes Endocrinol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2213-8595
DOI:10.1016/S2213-8587(24)00362-0